Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background and objectives Plasma biomarkers of Alzheimer disease (AD), neuroinflammation, and neurodegeneration are increasingly being used in clinical trials for diagnosis and monitoring of dementia. However, their association with longitudinal structural brain MRI changes, an important outcome measure across neurodegenerative and cerebrovascular diseases, is less known. We investigated how baseline plasma biomarkers reflect MRI markers of progression over time in patients with neurodegenerative and cerebrovascular diseases. Methods This longitudinal cohort study included patients from the Ontario Neurodegenerative Disease Research Initiative diagnosed with AD or mild cognitive impairment (AD/MCI), Parkinson disease (PD), frontotemporal dementia spectrum disorders (FTD), or cerebrovascular disease (CVD), followed annually for 2 years. Recruitment took place at specialized university-based dementia, movement disorders, and/or stroke clinics in the province of ON, Canada. MRI outcomes included markers of cerebral atrophy (ventricular CSF and regional gray matter volumes) and of small vessel disease pathology (white matter hyperintensity [WMH], perivascular spaces, and lacunar volumes). Hemorrhagic markers at baseline were also included. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau181 and tau217 (p-tau181, p-tau217), and β-amyloid (Aβ 42/40 ) were quantified from blood samples collected at baseline using Simoa and used as predictors in linear mixed models adjusted for time (months), age, sex, apolipoprotein E ( APOE )-ε4 carrier status, kidney function, vascular risk factors, microtubule-associated protein tau ( MAPT ) diplotypes, waist-hip circumference ratio, and disease duration. Results We analyzed 1,240 MRIs from 473 patients (age: 69.2 ± 7.4 [range: 49-87]; 32.8% women). Elevated baseline levels of GFAP, NfL, p-tau181, and p-tau217, and to a lesser extent decreased levels of Aβ 42/40 , were significantly associated with more cerebral atrophy and WMH burden at baseline (| B | = 0.02 to 1.69, p = 0.044 to B | = 0.001 to 0.028, p = 0.049 to Discussion Selected plasma biomarkers seem useful as prognosis and monitoring tools of longitudinal imaging changes within real-world populations of neurodegenerative and/or cerebrovascular diseases, and provide insight into overlap across diseases in shared pathologic burden.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 1,240 participants. In 473 patients with neurodegenerative or cerebrovascular diseases followed for 2 years, elevated baseline GFAP, NfL, p-tau181, and p-tau217 were associated with more brain atrophy and white matter hyperintensity burden. Reported effect size: 32.8%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sanchez, E., Coughlan, G. T., Wilkinson, T., Ramirez, J., Mirza, S. S., Baril, A. A., et al. (2025). Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases. Neurology. https://doi.org/10.1212/wnl.0000000000213438

Vancouver

Sanchez E, Coughlan GT, Wilkinson T, Ramirez J, Mirza SS, Baril AA, et al. Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases. Neurology. 2025. doi:10.1212/wnl.0000000000213438. PMID: 40063856.

BibTeX

@article{sanchez2025-40063856,
  author  = {Sanchez, E. and Coughlan, G. T. and Wilkinson, T. and Ramirez, J. and Mirza, S. S. and Baril, A. A. and Dilliott, A. A. and Frank, A. and others},
  title   = {{Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases}},
  journal = {Neurology},
  year    = {2025},
  doi     = {10.1212/wnl.0000000000213438},
  pmid    = {40063856},
  url     = {https://doi.org/10.1212/wnl.0000000000213438}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 473 patients with neurodegenerative or cerebrovascular diseases followed for 2 years, elevated baseline GFAP, NfL, p-tau181, and p-tau217 were associated with more brain atrophy and white matter hyperintensity burden. This is an observational biomarker-imaging study and does not test any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 67 of the 96 points it could be judged on, which is 70 of 100. Total 70 of 100.67 of the 96 points we could judge = 70 of 100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 67 of the 96 points we could judge it on, which is 70 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,240 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 32 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.7 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 20.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 49 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40063856)
Free to read 0 / 2 Behind a paywall — scores zero
Points 67 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 67 of the 96 points we could judge it on is 70 out of 100.
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →